Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)

A Multicenter, Open-label, Multiple-dose Escalation Phase Ⅰb Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease

This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial plans to enroll approximately 24 MASLD participants across four dose cohorts, each consisting of 6 participants who will receive oral ACT500 once daily.

Study Overview

• Status: Not yet recruiting
• Conditions: Metabolic Dysfunction-associated Steatohepatitis
• Intervention / Treatment: Drug: ACT500 tablets

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Lai Wei; Phone Number: 01056118930; Email: weelai@163.com

Study Locations

• China
  • Beijing, China
    • Beijing Tsinghua Changgeng Hospital
    • Contact: Lai Wei
  • Shanghai, China
    • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    • Contact: Jiangao Fan
  • Xi'an, China
    • The First Affiliated Hospital of Xi'an Jiaotong University
    • Contact: Yingli He
  • Xiamen, China
    • The First Affiliated Hospital of Xiamen University
    • Contact: Xiulan Xue

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The participant fully understands the purpose, nature, methods, and possible adverse reactions of the study, voluntarily participates in this study, and has signed the informed consent form.
• Male or female participants aged between 18 and 69 years (inclusive of 18 and 69 years) at the time of signing the informed consent form.
• Liver fat content (LFC) ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period.
• Liver stiffness measurement (LSM) assessed by FibroScan during the screening period meets the criteria of 8 kPa ≤ LSM ≤ 15 kPa, OR a liver biopsy pathological result of F2/F3 fibrosis within 6 months prior to screening.
• Serum alanine aminotransferase (ALT) levels meeting 2×ULN ≤ ALT ≤ 5×ULN at screening.

• Presence of at least one of the following metabolic risk factors:

  1. BMI ≥ 24.0 kg/m^2, or waist circumference ≥ 90 cm (males) and ≥ 85 cm (females);
  2. Presence of prediabetes: fasting blood glucose ≥ 6.1 mmol/L, or glycated hemoglobin (HbA1c) ≥ 5.7%;
  3. History of type 2 diabetes mellitus;
  4. Fasting serum triglycerides (TG) ≥ 1.70 mmol/L but < 5.6 mmol/L;
  5. Fasting serum high-density lipoprotein cholesterol (HDL-C) ≤ 1.0 mmol/L (males) and ≤ 1.3 mmol/L (females), OR currently receiving a stable dose of lipid-lowering medication;
  6. Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, while simultaneously meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg, OR currently receiving a stable dose of antihypertensive medication and meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg.

• Both male and female participants must agree to use appropriate contraceptive methods, as follows:

  1. For male participants: Agreement to use reliable contraceptive measures and refrain from sperm donation from signing the informed consent form until 3 months after the last dose.
  2. For female participants: Female participants of non-childbearing potential; OR female participants of childbearing potential who are not pregnant or breastfeeding, have a negative serum pregnancy test at screening and within 1 day prior to the first dose, and agree to use reliable contraceptive measures and refrain from egg donation from signing the informed consent form until 3 months after the last dose.

Exclusion Criteria:

• [1] Combined with other liver diseases, including but not limited to hepatitis B, hepatitis C, drug-induced liver disease, alcoholic liver disease, autoimmune liver disease, suspected or confirmed hepatocellular carcinoma, etc.

  [2] Have a history of or currently have other malignancies, liver cirrhosis (including confirmed or suspected liver cirrhosis by imaging examination, or liver cirrhosis confirmed by liver biopsy), or have evidence of decompensated liver disease (such as ascites, esophageal and gastric variceal bleeding, or hepatic encephalopathy, etc.), or have a history of liver transplantation.

  [3] Have a history of or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmias (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, etc.

  [4] Have a history of persistent, clinically significant respiratory, neurological, gastrointestinal, immunological, hematological, or psychiatric diseases, which, in the investigator's judgment, would pose additional risk to the participant.

  [5] Have type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose >9 mmol/L within 3 months prior to screening, or HbA1c >9.5% at screening), or are diabetic patients using glucose-lowering medications other than metformin.

  [6] Have an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² at screening or a history of severe renal impairment.

  [7] Have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia; or have hemoglobin <105 g/L for female participants or <115 g/L for male participants at screening; or any other condition known to interfere with hemoglobin measurement as judged by the investigator.

  [8] Have any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) > 2 × upper limit of normal (ULN), serum total bilirubin (TBIL) > 1.5 × ULN, or international normalized ratio (INR) > 1.3.

  [9] Have had a body weight change (increase or decrease) of >5% within 3 months prior to screening, or have undergone dieting, bariatric surgery, or used medications approved for weight loss indications.

  [10] Have a history of major trauma or surgery within 3 months prior to screening, or plan to undergo surgery during the study period.

  [11] Have a history of excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening, defined as a weekly ethanol intake of ≥210 g for males and ≥140 g for females; or have a history of drug abuse/dependence or a history of illicit drug inhalation/injection within 1 year prior to screening.

  [12] Have used medications that may have a therapeutic effect on MASLD/MASH (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, FGF21 analogs, resmetirom, etc.) or medications that may cause MASLD/MASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogens at doses greater than hormone replacement therapy, anabolic steroids, valproic acid, other known hepatotoxic drugs, etc.) within 3 months prior to screening, or other medications that the investigator considers may affect the trial.

  [13] Have participated in another drug clinical trial within 3 months prior to screening.

  [14] Have a positive test for any of the following at screening: human immunodeficiency virus antibody (HIV-Ab) or Treponema pallidum antibody.

  [15] Have a known allergy to the excipients of ACT500 or to drugs with a similar chemical structure to ACT500, or have other drug allergies that, in the investigator's judgment, preclude participation in the study.

  [16] Have any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study, or are unable to participate in the trial due to the participant's own reasons after signing the informed consent form (ICF).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 60 mg ACT500 tablet group	Drug: ACT500 tablets; Once daily, orally
Experimental: 160 mg ACT500 tablet group	Drug: ACT500 tablets; Once daily, orally
Experimental: 300 mg ACT500 tablet group	Drug: ACT500 tablets; Once daily, orally
Experimental: 400 mg ACT500 tablet group	Drug: ACT500 tablets; Once daily, orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Adverse Event#AE#	Day1-112
Serious Adverse Event	Day1-112
body temperature	Day 1,14,29,56,84,112
pulse	Day 1,14,29,56,84,112
heart rate	Day 1,14,29,56,84,112
blood pressure	Day 1,14,29,56,84,112
Number of Participants with Abnormal Laboratory Parameters Findings	Day 1,14,29,56,84,112
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v6.0	Day 1,14,29,56,84,112
Number of participants with clinically significant change from baseline in physical examination	Day 1,14,29,56,84,112
Heart Rate	Day 14,29,56,84,112,
PR Interval	Day 14,29,56,84,112,
QRS Interval	Day 14,29,56,84,112,
QT Interval	Day 14,29,56,84,112,
QTc Interval	Day 14,29,56,84,112,

Secondary Outcome Measures

Outcome Measure	Time Frame
Area Under Curve（0-t）	Day 1,2,14,28,29
Area Under the Concentration-time curve from time zero to τ at steady state	Day 1,2,14,28,29
Area Under Curve（0-∞）	Day 1,2,14,28,29
Maximum Plasma Concentration	Day 1,2,14,28,29
Time to Maximum (plasma) Concentration	Day 1,2,14,28,29
Elimination Half-Life	Day 1,2,14,28,29
CL/F	Day 1,2,14,28,29
Apparent Volume of Distribution	Day 1,2,14,28,29
Cmin,ss	Day 1,2,14,28,29
Cav,ss	Day 1,2,14,28,29
Rac_Cmax	Day 1,2,14,28,29
Rac_AUC0-tau	Day 1,2,14,28,29
DF	Day 1,2,14,28,29
MRI-PDFF-determined liver fat content (LFC)	Day 29,112
Fibroscan-measured liver stiffness measurement (LSM)	Day 29,112
AST/PLT Ratio Index，APRI	Day 1,14,29,56,84,112
absolute change from baseline in ELF	Day 1,14,29,56,84,112
percent change from baseline in ELF	Day 1,14,29,56,84,112
Total Cholesterol	Day 1,14,29,56,84,112
Triglyceride	Day 1,14,29,56,84,112
Low-Density Lipoprotein Cholesterol	Day 1,14,29,56,84,112
High-Density Lipoprotein Cholesterol	Day 1,14,29,56,84,112
apolipoprotein A1	Day 1,14,29,56,84,112
apolipoprotein B	Day 1,14,29,56,84,112
absolute change from baseline in lipoprotein(a)	Day 1,14,29,56,84,112
percent change from baseline in lipoprotein(a)	Day 1,14,29,56,84,112
Alanine Aminotransferase	Day 1,14,29,56,84,112
Aspartate Aminotransferase	Day 1,14,29,56,84,112
Gamma-Glutamyl Transferase（GGT）	Day 1,14,29,56,84,112
absolute change from baseline in GGT	Day 1,14,29,56,84,112
percent change from baseline in GGT	Day 1,14,29,56,84,112
body weight	Day 1,14,29,56,84,112
body Mass Index	Day 1,14,29,56,84,112
waist circumference	Day 1,14,29,56,84,112
absolute change from baseline in hip circumference	Day 1,14,29,56,84,112
High-sensitivity C-reactive protein	Day 1,2,14,28,29
Tumor Necrosis Factor alpha	Day 1,2,14,28,29
Cytokeratin 18 （M30）	Day 1,2,14,28,29
N-terminal propeptide of type III collagen (Pro-C3)	Day 1,14,29
absolute change from baseline in Pro-C3	Day 1,1429
percent change from baseline in Pro-C3	Day 1,14,29
Insulin-like Growth Factors-1	Day 1,14,29
Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)	Day 1,29
absolute change from baseline in IGFBP-3	Day 1,29
percent change from baseline in IGFBP-3	Day 1,29

Collaborators and Investigators

• Sponsor: Xiamen Amoytop Biotech Co., Ltd.
• Collaborators: Beijing Tsinghua Changgeng Hospital
• Investigators: Principal Investigator: Lai Wei, Beijing Tsinghua Changgeng Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): March 31, 2026
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: March 4, 2026
• First Submitted That Met QC Criteria: March 4, 2026
• First Posted (Actual): March 10, 2026

Study Record Updates

• Last Update Posted (Actual): March 17, 2026
• Last Update Submitted That Met QC Criteria: March 15, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: ACT500; NM6606; Metabolic Dysfunction-associated Steatohepatitis
• Other Study ID Numbers: ACT500-4-1-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No